PA
TXG icon

Perceptive Advisors’s 10x Genomics TXG Stock Holding History

Perceptive Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-220,000
Closed -$13.8M – 140
2020
Q1 		$13.8M Hold
220,000
– – 0.36% 50
2019
Q4 		$16.8M Hold
220,000
– – 0.33% 53
2019
Q3 		$11.1M Buy
+220,000
New +$12.2M 0.3% 54

Other funds holding TXG

VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Perceptive Advisors's TXG Position: Q2 2020 in Review

Perceptive Advisors sold out of 10x Genomics (TXG) in Q2 2020, closing a stake of 220,000 shares — an estimated $13.8M sold.

Perceptive Advisors first reported a position in TXG in Q3 2019 and held it in 3 quarters. The position peaked at $16.8M in Q4 2019. 146 funds tracked by Wall St. Rank hold TXG as of Q2 2020.

  • Perceptive Advisors reported no remaining 10x Genomics position as of Q2 2020 after selling out during the quarter.
  • Perceptive Advisors sold 220,000 10x Genomics shares in Q2 2020, an estimated $13.8M.
  • Perceptive Advisors first reported a position in 10x Genomics in Q3 2019 and held it in 3 quarters.
  • Perceptive Advisors's 10x Genomics position peaked at $16.8M in Q4 2019.
  • 146 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2020.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.